Taxane therapies are well-established, widely used, and effective anti-cancer treatments, representing an important component of the standard of care for many different cancers. However, as treatments, taxanes continue to have serious limitations both in terms of how they are administered and the wide range of often serious toxicities they cause. Overcoming these limitations could have an enormous positive impact on the lives of hundreds of thousands of cancer patients who are prescribed taxanes every year.

Modra is dedicated to addressing these challenges by applying its proprietary approach to improve taxane treatments for cancer patients. The company’s lead program, ModraDoc006/r, a boosted oral formulation of docetaxel, is developed to transform the experience of docetaxel therapy. For the large patient populations that are treated today with IV taxanes, this novel oral therapy has the potential to be equally effective in fighting tumors while offering a substantially better safety and tolerability profile and transforming the treatment paradigm with an oral tablet that can be taken conveniently at home. Reduced need for infusions, fewer hospital visits, and milder side effects would give patients more time to focus on what matters most.

Access our most recent press releases and news here